The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $32.87, denoting a +0.67% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily ...

The newly formed company will be named Decoy Therapeutics. This proposed transaction is expected to facilitate multiple value-creating inflection points with Decoy’s pipeline of peptide ...

However, Wall Street's enthusiasm for Summit Therapeutics appears to be justified. If ivonescimab fulfills its potential, Summit should be worth a lot more within a few years than it is today.

The upstart, clinical stage biotech company Viking Therapeutics, Inc. (NASDAQ:VKTX), which is attempting to disrupt their market leadership has also suffered from a protracted hangover ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Biodefense Market refers to strategies and technologies designed to protect populations from biological threats, including bioterrorism and accidental biological exposures. The use of medications, ...

With the huge research investment worldwide, the peptide-based therapeutics market is expected to grow manifolds in the future. (2) There are several peptide-based drugs available in the market ...

Dyne Therapeutics Inc.-5.60% $1.56B ...